THCE
THCE at a glance
Naturally occurring
Psychoactive
Cannabinoid type
Discovery year
Also known as
Molecular formula
C18H24O2
CB1 receptor interaction
CB2 receptor interaction
What is THCE?
THCE is a synthetic cannabinoid and short-chain THC homologue with very limited scientific research available. It has not been conclusively identified as a naturally occurring constituent of cannabis, so it is not currently classified as a phytocannabinoid. There is also not enough evidence to determine whether THCE produces meaningful intoxication in humans.
THCE has the same basic THC structure as Delta-9-THC, but contains a two-carbon (ethyl) side chain instead of the five-carbon (pentyl) side chain of Delta-9-THC. This shorter side chain substantially reduces its overall cannabinoid activity. Delta-8-THCE is a separate positional isomer that has also been studied experimentally.
THCE is generally produced synthetically for research and analytical purposes rather than extracted from cannabis. It is mainly available as purified analytical reference material, often supplied in solution. Reliable information about its neat appearance, viscosity, crystallisation behaviour, long-term stability and degradation products remains very limited.
THCE has appeared in scientific research since at least the early 1990s, mainly in studies comparing short-chain THC homologues. Research remains extremely limited, with no established human clinical evidence and major gaps regarding psychoactive effects, safety and physical properties. Its main scientific relevance is as a comparison compound for studying how side-chain length changes the properties of THC homologues.
How THCE works in the human body
THCE is expected to have weak CB1 activity because its two-carbon side chain is shorter than typically required for strong cannabinoid receptor activation. In contrast, shorter THC homologues appear to retain stronger activity at the TRPA1 channel, making TRPA1 a plausible mechanism through which THCE could influence pain, irritation and sensory signalling. Its main metabolite is 11-OH-THCE, but human pharmacology remains largely unknown.
CB1
The main cannabinoid receptor in the brain, responsible for THC’s intoxicating effects. Computational docking of Δ8-THCE predicts strong CB1 affinity (Ki approximately 3.9 nM, comparable to THC’s own 2.9 nM). However, research shows that alkyl side chains generally need at least three carbons to push the receptor’s “toggle switch”, and THCE’s two-carbon chain falls short of this. This raises the possibility that THCE binds CB1 tightly but activates it weakly or not at all, resembling how the related short-chain cannabinoid THCV behaves as a CB1 antagonist rather than agonist, though this remains a computational prediction that has not been tested in cell-based or human studies.
CB2
The main cannabinoid receptor in the immune system, involved in regulating immune cell activity and inflammatory responses. No published binding or functional data exist for THCE at CB2. Related short-chain cannabinoids such as THCV bind CB2 with affinity similar to CB1, making a comparable interaction plausible for THCE, but this has not been directly studied or confirmed.
TRPA1 channel
TRPA1 is a sensory ion channel involved in pain, irritation and inflammatory signalling. Research on THC homologues suggests that shortening the alkyl side chain reduces CB1 activity much more strongly than TRPA1 activity, with very short-chain cannabinoids retaining notable TRPA1 activation. The one-carbon homologue THCC has been experimentally confirmed as a TRPA1 agonist, making similar activity plausible for the two-carbon THCE.
If THCE also acts as a TRPA1 agonist, activation would initially increase sensory nerve signalling, potentially increasing irritation or pain. Continued activation can then desensitise TRPA1 and reduce further pain signalling, which may produce an overall pain-reducing effect. This net analgesic effect has been demonstrated for THCC, but has not yet been confirmed specifically for THCE.
Metabolism
Based on the established metabolism of related THC homologues, 11-OH-THCE is a plausible intermediate in this pathway, but its formation and pharmacological activity have not been characterised directly. Several additional hydroxylated THCE metabolites have also been identified.
Human THCE metabolism has not yet been characterised, so it remains unknown which enzymes are primarily responsible, whether humans produce the same metabolites, and whether 11-OH-THCE or other THCE metabolites are pharmacologically active.
Human safety status
No human trials, toxicology studies or pharmacokinetic data exist for THCE. Only computational binding predictions are available, with no cell-based, animal or human testing identified. Its likely safety profile is inferred by analogy to other short-chain cannabinoids like THCV, not from direct evidence.
THCE interactions with other compounds
Important disclaimer
This information is provided for educational and technical reference only. Interaction data can change as new research becomes available and may be incomplete or outdated. The real relevance of any interaction depends strongly on dose, route of administration, timing, formulation and individual metabolism. Readers should do their own research and consult a qualified healthcare professional before making decisions involving medicines, alcohol, nicotine, cannabinoids or other compounds. Elementra's products and information are intended for research, production and technical use only and are not intended for human consumption.
No Known Interactions Identified
Current Evidence
Limited Data
No sufficiently supported specific interactions between THCE and other cannabinoids, common substances or medicines have currently been identified. There are no THCE-specific studies showing that another compound meaningfully changes THCE exposure or effects, or that THCE meaningfully changes the exposure or effects of another compound. This should not be interpreted as THCE having no interactions. Interactions may exist, but they have not yet been identified or characterized by research.
This content does not constitute advice
All information in the Cannabinoid Knowledge Hub is provided solely for educational and scientific purposes. It does not constitute medical advice, usage advice, dosage guidance or instructions for mixing, combining or consuming substances.
Discussions of effects, interactions and risks are descriptive only and should not be interpreted as a recommendation or encouragement to use or combine any substance. Visitors are responsible for complying with all applicable laws and regulations in their country or jurisdiction. Nothing in the Knowledge Hub may be used to support illegal activity.
Read the full disclaimer